Research Article
NAT10-mediated mRNA N4-acetylcytidine Reprograms Serine Metabolism to Drive Leukemogenesis and Stemness in Acute Myeloid Leukemia
Subo Zhang#, Feng Huang#, Yushuai Wang#, Yifei Long#, Yuanpei Li, Yalin Kang, Weiwei Gao, Xiuxin Zhang, Yueting Wen, Yun Wang, Lili Pan, Youmei Xia, Zhoutian Yang, Ying Yang, Hongjie Mo, Baiqing Li, Jiacheng Hu, Yunda Song, Shilin Zhang, Shenghua Dong, Xiao Du, Yingmin Li, Yadi Liu, Wenting Liao, Yijun Gao, Yaojun Zhang, Hongming Chen, Yang Liang, Jianjun Chen, Hengyou Weng*, Huilin Huang*. Nature Cell Biology 2024, https://doi.org/10.1038/s41556-024-01548-y
Full Text PDF: NAT10-mediated mRNA N4-acetylcytidine Reprograms Serine Metabolism to Drive Leukemogenesis and Stemness in Acute Myeloid Leukemia
The m6A Reader IGF2BP2 Regulates Glutamine Metabolism and Represents a Therapeutic Target in Acute Myeloid Leukemia
Hengyou Weng#,*, Feng Huang#, Zhaojin Yu#, Zhen-Hua Chen#, Emily Prince, Yalin Kang, Keren Zhou, Wei Li, Jiacheng Hu, Chen Fu, Tursunjan Aziz, Hongzhi Li, Jingwen Li, Ying Yang, Li Han, Subo Zhang, Yuelong Ma, Mingli Sun, Huizhe Wu, Zheng Zhang, Mark Wunderlich, Sean Robinson, Daniel Braas, Johanna ten Hoeve, Bin Zhang, Guido Marcucci, James C Mulloy, Keda Zhou, Hong-Fang Tao, Xiaolan Deng, David Horne, Minjie Wei*, Huilin Huang*, and Jianjun Chen*. Cancer Cell 2022, 40 (12): 1566-1582. e10.
PMID: 36306790
Full Text PDF: The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia
METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification
Weng H#, Huang H#, Wu H#, Qin X#, Zhao BS#, Dong L#, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M*, He C*, and Chen J*. Cell Stem Cell 2018, 22: 191-205.
PMID:29290617
Full Text PDF: METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification
Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally
Huang H#, Weng H#, Zhou K#, Wu T#, Zhao BS#, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu Y-C, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan J-L, Qu L, Wei M, Muschen M, Huang G*, He C*, Yang J*, and Chen J*. Nature 2019, 567:414-419.
PMID: 30867593
Full Text PDF: Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase
Li Z#, Weng H#, Su R#, Weng X#, Zuo Z#, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C*, Chen J*. Cancer Cell 2017, 31:127-141.
PMID：28017614
Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability and Translation
Huang H#, Weng H#, Sun W#, Qin X#, Shi H#, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C*, Yang J*, Chen J*. Nature Cell Biology 2018, 20:285-295.
PMID：29476152
Full Text PDF: Recognition of RNA N6-methyadenosine by IGF2BP proteins Enhances mRNA Stability and Translation
Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S
Weng H#, Huang H#, Dong B, Zhao P, Zhou H*, Qu L*. Cancer Research 2014, 74: 4409-4419.
PMID：24872388
Translational repression of cyclin D3 by a stable G-quadruplex in its 5’ UTR: implications for cell cycle regulation
Weng H#, Huang H#, Zhao P, Zhou H*, Qu L*. RNA Biology 2012, 9: 1099-1109.
PMID：22858673
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis
Huang H#, Weng H#, Wang L, Yu C, Huang Q, Zhao P, Wen J, Zhou H*, Qu L*. Molecular Cancer Therapeutics 2012, 11: 1155-1165.
PMID：22389469
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia
Huang H#, Weng H#, Dong B, Zhao P, Zhou H*, and Qu L*. Scientific Reports 2017, 7: 41525.
PMID：28128329
Overexpression and knockout of miR-126 both promote leukemogenesis
Li Z#*, Chen P#, Su R#, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, and Chen J*. Blood 2015; 126: 2005-2015.
PMID：26361793
Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles
Jiang X#*, Bugno J#, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S*, and Chen J*. Cancer Research 2016; 76: 4470-4480.
PMID：27280396
PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease
Li Z#, Chen P#, Su R#, Hu C#, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, and Chen J*. Cancer Research 2016; 76: 619-629.
PMID：26747896
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia
Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, and Chen J*. Nature Communications 2016; 7: 11452.
PMID：27116251
Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia
Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, and Chen J*. Cancer Letters 2016; 372: 157-165.
PMID：26791235
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
Jiang X#*, Hu C#, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy J, Zheng Y, Diao J, Jin J, Liu PP, Chen Y, and Chen J*. Nature Communications 2017; 8: 2099.
PMID：29235481
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling
Su R#, Dong L#, Li C#, Nachtergaele S#, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J*, He C*, and Chen J*. Cell 2018; 172: 90-105. Highlighted (Research Watch) by Cancer Discovery (2018 Feb;8(2):137).
PMID：29249359
RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia
Shen C#, Sheng Y#, Zhu AC#, Robinson S#, Jiang X#, Dong L#, Chen H#, Su R, Yin Z, Li W, Deng X, Chen Y, Hu Y-C, Weng H, Huang H, Prince E, Cogle CR, Sun M, Zhang B, Chen C-W, Marcucci G, He C*, Qian Z*, Chen J*. Cell Stem Cell 2020, 27: 64-80.
PMID：32402250
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Su R#, Dong L#, Li Y#, Gao M#, Han L#, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, Qin X, Prince E, Xie J, Qin H, Li W, Shen C, Sun J, Kulkarni P, Weng H, Huang H, Chen Z, Zhang B, Wu X, Olsen M, Muschen M, Marcucci G, Salgia R, Li L, Fathi AT, Li Z, Mulloy JC, Wei M, Horne D, Chen J*. Cancer Cell 2020, 38:79-96.
PMID：32531268
Review Article
Crosstalk between histone/DNA modifications and RNA N6-methyladenosine modification
Wang Y#, Huang H#, Chen J*, and Weng H*. Current Opinion in Genetics & Development 2024, 86:102205.
PMID: 38776766
Full Text PDF: Crosstalk between histone/DNA modifications and RNA N6-methyladenosine modification
Roles of METTL3 in cancer: mechanisms and therapeutic targeting
Zeng C#, Huang W#, Li Y*, Weng H*. Journal of Hematology & Oncology 2020, 13:117.
PMID：32854717
Full Text PDF: Roles of METTL3 in cancer: mechanisms and therapeutic targeting
N6‐methyladenosine Steers RNA Metabolism and Regulation in Cancer
Dong S#, Wu Y#, Liu Y#, Weng H*, Huang H*. Cancer Communications 2021, 41:538-559.
Full Text PDF: N6‐methyladenosine Steers RNA Metabolism and Regulation in Cancer
The Biogenesis and Precise Control of RNA m6A Methylation
Huang H#, Weng H#, Chen J. Trends in Genetics 2019, 36: 44-52.
PMID：31810533
m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer
Huang H#, Weng H#, Chen J. Cancer Cell 2020, 37: 270-288.
PMID：32183948
RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications
Huang H, Weng H, Deng X, Chen J. Annual Review of Cancer Biology 2020, 4: 221-240.
The pathological role and prognostic impact of miR-181 in acute myeloid leukemia
Weng H, Lal K, Yang F, Chen J. Cancer Genetics 2015, 208: 225-229.
PMID：25686674
Attacking c-Myc: Targeted and Combined Therapies for Cancer
Huang H#, Weng H#, Zhou H*, Qu L*. Current Pharmaceutical Design 2014, 20: 6543-6554.
PMID：25341931
RNA N6-methyladenosine modification in cancers: current status and perspectives
Deng X*, Su R, Weng H, Huang H, Li Z, Chen J*. Cell Research 2018, doi:10.1038/s41422-018-0034-6.
PMID：29686311
Book Chapter
RNA N6-Methyladenosine Modification in Normal and Malignant Hematopoiesis
Weng H, Huang H, Chen J. Leukemia Stem Cells in Hematologic Malignancies, 2019: 75-93. Springer Nature Singapore.
N6-Methyladenosine RNA Modification in Normal and Malignant Hematopoiesis
Weng H#*, Huang H#*, Chen J*. Hematopoietic Stem Cells: Keystone of Tissue Development and Regenerative Medicine, 2024: 105-123. Springer Nature Singapore.
PMID：38228961
Full Text PDF: N6-Methyladenosine RNA Modification in Normal and Malignant Hematopoiesis
Granted Patent
1) 翁桁游，黄慧琳，周惠，屈良鹄。miR-17-5p 及 miR-20a 在制备依托泊苷耐药逆转剂中的应用。中国，授权公告日：2016-01-27；专利号：ZL201310274073.5
2) 翁桁游，黄慧琳，周惠，屈良鹄。冬凌草甲素联合依托泊苷在制备抗肿瘤药物中的应用。中国，授权公告日：2016-08-10；专利号：ZL201310274073.5
3) 黄慧琳，翁桁游，周惠，屈良鹄。冬凌草甲素在制备 FBW7 抑癌蛋白激活剂中的应用。中国，授权公告日：2013-08-28；专利号：ZL201110413556.X.